Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3

Active, not recruiting

Conditions: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Interventions: Drug: Imatinib
Drug: Asciminib
Drug: Nilotinib
Drug: Bosutinib
Drug: Dasatinib

First Posted Date: 2021-07-21

Last Posted Date: 2024-05-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 404

Registration Number: NCT04971226

Locations: 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸
Texas Oncology Austin, Dallas, Texas, United States
🇺🇸
Texas Oncology Texas Onc - Amarillo, Dallas, Texas, United States

and more 12 locations

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

Phase 2

Recruiting

Conditions: Gastrointestinal Stromal Tumor
Progression-free Survival
Neoadjuvant

Interventions: Drug: Imatinib

First Posted Date: 2021-06-22

Last Posted Date: 2021-10-12

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 122

Registration Number: NCT04933669

Locations: 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Asciminib Roll-over Study

Phase 4

Recruiting

Conditions: Chronic Myelogenous Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions: Drug: Bosutinib
Drug: Imatinib
Drug: Asciminib single agent
Drug: Nilotinib
Drug: Dasatinib

First Posted Date: 2021-05-07

Last Posted Date: 2024-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 347

Registration Number: NCT04877522

Locations: 🇺🇸
Michigan Med University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States

and more 2 locations

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Phase 2

Recruiting

Conditions: Chronic Phase Chronic Myelogenous Leukemia

Interventions: Drug: Asciminib 40 MG
Drug: Asciminib 40 MG Twice Daily
Drug: Asciminib 80 MG daily
Drug: Imatinib
Drug: Dasatinib
Drug: Nilotinib

First Posted Date: 2021-04-08

Last Posted Date: 2024-04-03

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 51

Registration Number: NCT04838041

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
The Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 1 locations

Study in Adult Ph-positive ALL

Phase 2

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia, Adult

Interventions: Drug: Imatinib
Drug: Ponatinib
Drug: Blinatumomab

First Posted Date: 2020-12-30

Last Posted Date: 2020-12-30

Lead Sponsor: Cardiff University

Target Recruit Count: 180

Registration Number: NCT04688983

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Phase 2

Recruiting

Conditions: Melanoma Stage III
Melanoma Stage IV

Interventions: Drug: Binimetinib
Drug: Imatinib

First Posted Date: 2020-10-22

Last Posted Date: 2024-08-22

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 25

Registration Number: NCT04598009

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia
Chronic Myeloid Leukemia in Remission
BCR-ABL Positive Chronic Myelogenous Leukemia

Interventions: Drug: Imatinib
Drug: Nilotinib
Drug: Dasatinib
Drug: Bosutinib

First Posted Date: 2020-10-08

Last Posted Date: 2020-10-08

Lead Sponsor: National Research Center for Hematology, Russia

Target Recruit Count: 100

Registration Number: NCT04578847

Locations: 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation

Trial of Imatinib for Hospitalized Adults With COVID-19

Phase 3

Active, not recruiting

Conditions: COVID-19

Interventions: Drug: Placebo oral tablet
Drug: Imatinib

First Posted Date: 2020-05-19

Last Posted Date: 2024-08-27

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 204

Registration Number: NCT04394416

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Phase 3

Active, not recruiting

Conditions: COVID-19

Interventions: Drug: LSALT Peptide
Drug: Artesunate
Drug: Imatinib
Drug: Infliximab
Drug: Dexamethasone

First Posted Date: 2020-04-01

Last Posted Date: 2023-10-13

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 2900

Registration Number: NCT04330690

Locations: 🇨🇦
Health Sciences Centre, Winnipeg, Manitoba, Canada
🇨🇦
Trillium Health Partners -Mississauga Site, Mississauga, Ontario, Canada
🇨🇦
Grey Nuns Community Hospital, Edmonton, Alberta, Canada

and more 50 locations

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Phase 3

Recruiting

Conditions: Leukemia, Acute Lymphoblastic

Interventions: Drug: Omitted Vincristine+Dexamethasone pulses
Drug: Blinatumomab
Drug: Omitted Doxorubicin
Drug: Inotuzumab Ozogamicin+Standard Maintenance Therapy
Drug: 6-tioguanine+Standard Maintenance Therapy
Drug: Imatinib

First Posted Date: 2020-03-13

Last Posted Date: 2024-07-12

Lead Sponsor: Mats Heyman

Target Recruit Count: 6430

Registration Number: NCT04307576

Locations: 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪
Klinikum Bremen Mitte, Bremen, Germany
🇩🇪
Universitätsmedizin Mainz, Mainz, Germany

and more 128 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy